Anrotinib is a new drug developed independently by the country and listed in the last two years, mainly for lung cancer progressing after third-line chemotherapy such as second-line treatment. The mechanism of action of Anrotinib is to block angiogenesis, which is generally applied in small doses at the beginning, commonly used in two sizes, 8mg and 12mg, and the dosing regimen is generally 2 weeks of administration and 1 week of discontinuation, 3 weeks is considered a course of treatment, after 3 weeks, according to the adverse reactions of patients in the middle to determine whether it is appropriate to continue to use, whether to increase or decrease the dosage, and adjust the treatment regimen through the efficacy. How long it takes for the drug to be effective is based on a comprehensive clinical assessment. For example, whether the patient has other lesions or metastatic lesions, the clinician will make a comprehensive assessment based on the patient’s condition. In general, the drug regimen is 2 weeks of administration and 1 week of discontinuation, a course of treatment of about 21 days. The most important adverse effect is bleeding. If a patient experiences massive gastrointestinal bleeding while taking the drug, it is important to assess whether to continue taking the drug and whether to stop or reduce the dosage. The dosage and duration of treatment vary from person to person and from treatment plan to treatment plan, so the medication is a dynamic adjustment process.